老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
醫藥生物股
659.123
+7.690
1.18%
漲家數：
9
跌家數：
13
平家數：
21
市盈率：
- -
高：
659.836
開：
650.308
低：
649.787
收：
651.433
成交量：
5,357.51萬
成交額：
1.75億
市值：
939.69億
流通市值：
908.01億
資料載入中...
總覽
新聞資訊
Mayne Pharma集團與Italfarmaco簽署澳大利亞Blissel獨家五年許可協議
美股速递
·
昨天
英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者
路透中文
·
09/01
CSL重大擴產計劃：大幅提升免疫球蛋白及白蛋白生產能力，惠及罕見病與重症患者
美股速递
·
09/01
CSL達成協議：為美國藥品定價及特定232條款關税風險增添確定性
美股速递
·
09/01
CSL有限公司：項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位
美股速递
·
09/01
CSL與美國政府達成協議 降價藥品並助力本土製造投資
美股速递
·
09/01
CSL有限公司：新協議助力降低療法價格，彰顯15億美元擴建伊利諾伊州美國產能計劃
美股速递
·
09/01
特朗普政府將宣佈藥品定價協議
路透中文
·
09/01
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK7508/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"醫藥生物股","latestPrice":659.12286,"timestamp":1789451999873,"preClose":651.433,"halted":0,"volume":53575081,"delay":0,"changeRate":0.011805,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":7.68988,"latestTime":"09-15 16:00:00 AEST","open":650.3083,"high":659.83606,"low":649.7866,"amount":174754998,"amplitude":0.015427,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789430400000,1789452000000]],"turnoverRate":0.002101,"increases":12,"decrements":14,"flats":17,"marketCap":93968924033.25,"floatMarketCap":90800532130.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":659.83606,"amplitude":0.015427,"preClose":651.433,"low":649.7866,"latestPrice":659.12286,"volume":53575081,"delay":0,"open":650.3083,"prevYearClose":644.3692,"prevWeekClose":634.95,"prevMonthClose":656.138,"prevQuarterClose":464.145,"fiveDayClose":665.136,"twentyDayClose":622.013,"sixtyDayClose":449.629,"secType":"PLATE","market":"AU","turnoverRate":0.002101,"marketCap":93968924033.25,"floatMarketCap":90800532130.125,"timestamp":1789451999873,"nameCN":"醫藥生物股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":9,"down":13,"flat":21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132428558","title":"Mayne Pharma集團與Italfarmaco簽署澳大利亞Blissel獨家五年許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1132428558","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132428558?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:52","pubTimestamp":1789429933,"startTime":"0","endTime":"0","summary":"Mayne Pharma集团宣布，已与Italfarmaco S.a签署了一项为期五年的独家许可协议。该协议针对Blissel在澳大利亚市场的推广与分销权。此举标志着Mayne Pharma在女性健康领域的战略布局进一步深化。Mayne Pharma方面表示，此次合作契合其专注于专科治疗领域的长期发展策略。通过引入Blissel这一产品，公司意在强化其在澳大利亚医疗市场中的竞争地位。而Italfarmaco则借助Mayne Pharma的本地网络，实现产品的快速渗透与市场拓展。投资者可密切关注该合作对Mayne Pharma营收结构的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664347855","title":"英國監管機構因數據不可靠，暫停安進公司Tavneos用於新患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2664347855","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664347855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:15","pubTimestamp":1788261324,"startTime":"0","endTime":"0","summary":"英国监管机构因数据不可靠，暂停安进公司Tavneos用于新患者路透9月1日-英国药品监管机构周二暂停了安进公司旗下AMGN.O研发的罕见病药物Tavneos对新患者的使用和销售，称支持该药获批的主要研究结果不可靠。监管机构表示，由于主要临床试验的数据不可靠，该研究已无法证明该药有效，也无法证明其益处大于风险。Tavneos由ChemoCentryx公司研发，安进公司于2022年以37亿美元收购了该公司。欧洲委员会于8月撤销了Tavneos的批准，此前监管机构发现其关键试验数据不可靠。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T10B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","LU0058720904.USD","LU0889565916.HKD","LU2242646821.SGD","IE0002141913.USD","LU0868494617.USD","BK4581","LU1571399168.USD","LU2089984988.USD","BK7508","IBBQ","LU2112291526.USD","BK4139","IE00BJT1NW94.SGD","LU1023059063.AUD","IBB","LU1983299246.USD","LU0289739699.SGD","LU0122379950.USD","TBXU","SG9999001440.SGD","BK4588","LU1061106388.HKD","CSL.AU","IE00B2B36J28.USD","PBE","BK4533","IE00BJJMRZ35.SGD","BK7067","LU2242652126.USD","LU2468319806.SGD","BK7511","AMGN","BIB","IE00BFTCPJ56.SGD","PJP","LU1057294990.SGD","BBH","LU0320765992.SGD","BK7501","LU0109394709.USD","BK4534","BK4585","BK4566","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160995524","title":"CSL重大擴產計劃：大幅提升免疫球蛋白及白蛋白生產能力，惠及罕見病與重症患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1160995524","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160995524?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:27","pubTimestamp":1788204431,"startTime":"0","endTime":"0","summary":"CSL宣布了一项重大扩建项目，此举将显著增强其为罕见疾病及严重病症患者生产免疫球蛋白和白蛋白的能力。这一战略性举措不仅标志着公司在生物制药领域迈出的坚实一步，更意味着全球更多患者有望获得这些关键性治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181327820","title":"CSL達成協議：為美國藥品定價及特定232條款關税風險增添確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1181327820","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181327820?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:25","pubTimestamp":1788204309,"startTime":"0","endTime":"0","summary":"CSL宣布，已通过相关协议为其在美国药品定价及部分第232条款关税方面的潜在风险敞口提供了更多确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194972911","title":"CSL有限公司：項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位","url":"https://stock-news.laohu8.com/highlight/detail?id=1194972911","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194972911?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:24","pubTimestamp":1788204248,"startTime":"0","endTime":"0","summary":"CSL有限公司宣布，其新项目将带来显著的就业增长。据估计，该项目将直接催生至少300个制药制造领域的全新工作岗位。与此同时，建筑业及相关配套行业也将迎来约800个就业机会。这一系列的岗位创造计划，无疑将为当地经济注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100124360","title":"CSL與美國政府達成協議 降價藥品並助力本土製造投資","url":"https://stock-news.laohu8.com/highlight/detail?id=1100124360","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100124360?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:23","pubTimestamp":1788204189,"startTime":"0","endTime":"0","summary":"生物技术巨头CSL已与美国政府签署新协议，旨在降低部分药品价格，同时加大对美国本土生产设施的投资力度。此举被视为制药行业响应政府控价压力、巩固供应链安全的最新动向之一。根据协议内容，该公司将在积极推进制造业扩张的同时，向市场提供更具竞争力的定价。业界分析指出，这一安排既反映了企业在政策环境下的策略调整，也凸显了医疗健康领域对成本控制与产能韧性的双重诉求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171032857","title":"CSL有限公司：新協議助力降低療法價格，彰顯15億美元擴建伊利諾伊州美國產能計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1171032857","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171032857?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:23","pubTimestamp":1788204189,"startTime":"0","endTime":"0","summary":"CSL有限公司宣布，一系列新达成的协议将支持其疗法产品价格的进一步下调，并充分体现了该公司斥资15亿美元用于扩建其位于伊利诺伊州的美国生产基地的宏伟蓝图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002674","title":"特朗普政府將宣佈藥品定價協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002674","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002674?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 00:07","pubTimestamp":1788192474,"startTime":"0","endTime":"0","summary":"特朗普政府将宣布药品定价协议预计拜耳、武田、CSL以及中型生物技术公司将达成新协议路透此前曾报导，小型制药商认为参与其中的财务激励有限美国处方药价格往往是其他发达国家的近三倍路透8月31日-白宫一名官员表示，美国总统唐纳德·特朗普 预计将于周一宣布新一轮药品定价协议，这是旨在降低美国民众医疗保健成本举措的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4T44S1CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","LU1868837136.USD","LU2750360641.GBP","THNR","OZEM","IBBQ","BK7508","LU2361044949.HKD","GB00BDT5M118.USD","LU2746668974.SGD","MEDI","SG9999013999.USD","IE00B2B36J28.USD","LU0198837287.USD","SGXZ99366536.SGD","BK4139","ILDR","SG9999014880.SGD","LU0432979614.USD","LU0320765059.SGD","LU0385154629.USD","LU1035775433.USD","LU2417539215.USD","SG9999001176.USD","IXJ","LU2471134796.USD","LU1066051498.USD","IE00BJJMRY28.SGD","LU0170899867.USD","LU2462591350.SGD","LU0079474960.USD","LU2089984988.USD","LU0320765992.SGD","SG9999015978.USD","LU0266013472.USD","LU0225283273.USD","BK4516","LU1691799644.USD","LU2361044865.SGD","LU2552382058.USD","LU1548497426.USD","LU1061106388.HKD","LU2360106947.USD","LU0353189763.USD","LU1291159041.SGD","LU2265009873.SGD","SG9999014906.USD","LU1720051017.SGD","LLYZ","LU2028103732.USD","LU2168564222.USD","IE0002141913.USD","LU1868836757.USD","LU2213496289.HKD","LU0823434583.USD","LU1868836914.USD","CURE","IE00B1XK9C88.USD","LU2746668461.USD","LU0787776722.HKD","LU1145028129.USD","LU0210536198.USD","LU0203202063.USD","LU0256863811.USD","LU2324357040.USD","LU2552382132.HKD","SG9999011175.SGD","BK4581","LLYX","LU1093756168.USD","IE00B4JS1V06.HKD","LU2023250504.SGD","LU1983299246.USD","LLII","BK4533","IE0004445015.USD","LU1093756325.SGD","LU2236285917.USD","LU2602419157.SGD","LU0106261372.USD","LU2106854487.HKD","IE0002270589.USD","LU1023059063.AUD","LU0353189680.USD","SG9999014914.USD","BK7511","LU1989771016.USD","LU0097036916.USD","BK4566","LU0689472784.USD","LU1069344957.HKD","LU0708995401.HKD","LU1571399168.USD","LU1883839398.USD","IE000M9KFDE8.USD","LU0820561909.HKD","SG9999002232.USD","LU0672654240.SGD","IE00B7KXQ091.USD","LU0466842654.USD","LU0234572021.USD","CANC","IE0004445239.USD","IE00B4R5TH58.HKD","LU2063271972.USD","LU0225771236.USD","LU2111349929.HKD","CSL.AU","LU0786609619.USD","SG9999001440.SGD","SG9999015945.SGD","PJP","SGXZ57979304.SGD","IE00BJJMRX11.SGD","SG9999003800.SGD","IE00BFSS8Q28.SGD","LU2023250330.USD","LU2471134952.CNY","RXL","BK7501","LU0882574139.USD","LU1280957306.USD","LU1814569148.SGD","LU0417517546.SGD","IE00B3T34201.USD","FHLC","ELIS","LU0471298777.SGD","PBE","IE00BJT1NW94.SGD","SG9999017495.SGD","LU0061475181.USD","SG9999015952.SGD","LU0133085943.USD","LU2112291526.USD","TMED","SG9999015986.USD","IE00BLSP4239.USD","BBH","LU1064131342.USD","LU1868837300.USD","LU2168563687.JPY","BK4599","BK4550","LU0158827948.USD","LU1712237335.SGD","MHIP","LU0889565916.HKD","LU2896262040.SGD","04332","IE00BWXC8680.SGD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU2168564065.EUR","LU2468319806.SGD","LU0868494617.USD","LU2491049909.HKD","IONS","IE00BBT3K403.USD","LU0203201768.USD","LU2089284900.SGD","LU0323591593.USD","SG9999001176.SGD","LU1366192091.USD","LU2237438978.USD","BK4585","LU2271345857.HKD","LU2756315664.SGD","IE0009355771.USD","SG9999018865.SGD","LU0321505439.SGD","LU0820561818.USD","LU1057294990.SGD","IYH","LU2242646821.SGD","BK4568","LU2456880835.USD","LU0964807845.USD","LU1974910355.USD","LU0823416689.USD","LU0114720955.EUR","LU1868836591.USD","SGXZ51526630.SGD","LU0158827781.USD","LU1804176565.USD","LU2242652126.USD","LU2264538146.SGD","LU2237443622.USD","SGXZ31699556.SGD","LU2471134523.USD","LU0094547139.USD","LU0306807586.USD","LU2089283258.USD","LU1979441026.SGD","PFE","XLV","LU0354030511.USD","LU2491050071.SGD","LU0943347566.SGD","VHT","LU0985481810.HKD","BK4534","ELIL","IE00BN29S564.USD","LU0225284248.USD","LU1917777945.USD","SG9999002224.SGD","LU2211815571.USD","LU0823434740.USD","BK7067","HRTS","IE00B19Z3B42.SGD","PPH","LU2168564149.EUR","LU0316494557.USD","LU2237443549.SGD","LU2596442595.SGD","LU1127390331.HKD","LU0345770993.USD","LU1988902786.USD","IE00BKDWB100.SGD","LU0174119429.USD","LU0256863902.USD","LU2108987350.USD","LU0354030438.USD","LU0820562030.AUD","LU2462157665.USD","IE0005OL40V9.USD","LU0345770308.USD","LU0109394709.USD","LU1267930730.SGD","LU0109391861.USD","LU0306806265.USD","BK4588","AGNG","LU0683600562.USD","IE00B775H168.HKD","IE00BLSP4452.SGD","IBB","IE00BJLML261.HKD","LU1551013342.USD","LLY","AMGN","BK4007","LU0289739699.SGD","LU1894683348.USD","LU0456855351.SGD","LU2361045086.USD","SG9999018857.SGD","LU0122379950.USD","LU1623119135.USD","IHE","GDOC","LU2023251221.USD","IE00BKPKM429.USD","LU2357305700.SGD","LU2461242641.AUD","LU2491050154.USD","LU2552382215.SGD","SGXZ81514606.USD","TBXU","IE00B19Z3581.USD","LU1066053197.SGD","LU1232071149.USD","LU2750360997.AUD","IE00BFTCPJ56.SGD","LU2237443895.HKD","IE0001KFT4U8.USD","IE00BK4W5L77.USD","LU0471298694.HKD","JDOC","LU2168564495.EUR","LU1894683264.USD","LU1720051108.HKD","SG9999014898.SGD","LU2237443382.USD","IE00BFSS7M15.SGD","IE00BK4W5M84.HKD","LU0238689110.USD","BIB","LU2087625088.SGD","LU0096364046.USD","LU2237443465.HKD","LU2237443978.SGD","LU0640476718.USD","WDNA","FTXH","LU2756315318.SGD","LU0882574055.USD","IE00B1BXHZ80.USD","LU1323610961.USD","BK4592","LU2471134879.HKD","TRUH","LU0058720904.USD","MEDX","LU1551013425.SGD","LU1629891620.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}